Fluorometric Imaging for Early Diagnosis and Prognosis of Rheumatoid Arthritis
Source abstract
Abstract
Abstract Early diagnosis and monitoring of disease progress are of significant importance in the effective treatment of rheumatoid arthritis (RA), because the continuing inflammation can lead to irreversible joint damage and systemic complications. However, applying imaging modalities for the prognosis of RA remains challenging, because no tissue‐specific guidelines are available to monitor the progressive course of RA. In this study, fluorometric imaging of RA is reported using bioengineered targeted agents of the blood vessel, bone, and cartilage in combination with the customized optical fluorescence imaging system. Separate but simultaneous tissue‐specific images of synovitis, cartilage destruction, and bone resorption are obtained from a mouse model of RA, which allows quantification of the prognosis of diseases at each stage. Thus, the fluorometric imaging of RA by using tissue‐specific contrast agents plays a key role in the systemic treatment of RA by monitoring structural damage and disease progression.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Orthopedic Infections and Treatments · Extracellular vesicles in disease · Rheumatoid Arthritis Research and Therapies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Gordon Center for Medical Imaging Department of Radiology Massachusetts General Hospital and Harvard Medical School Boston MA 02114 USA
Division of Rheumatology Department of Internal Medicine CHA Bundang Medical Center CHA University Seongnam 13496 South Korea
Department of Biomedical Sciences Chonnam National University Medical School Gwangju 501‐746 South Korea
Funding
National Institutes of Health · National Heart, Lung, and Blood Institute · National Cancer Institute · National Research Foundation of Korea
References (36)
Show source-provided references
1. 10.1093/rheumatology/kes11310.1093/rheumatology/kes113 ↗
2. 10.1038/nrrheum.2016.19410.1038/nrrheum.2016.194 ↗
3. Picerno V. · Clin. Exp. Rheumatol. · 2015 · 33 · 551
4. 10.1038/nrrheum.2015.9510.1038/nrrheum.2015.95 ↗
5. 10.1016/j.berh.2011.10.00210.1016/j.berh.2011.10.002 ↗
6. 10.1093/rheumatology/kes32910.1093/rheumatology/kes329 ↗
7. 10.2217/ijr.10.10510.2217/ijr.10.105 ↗
8. 10.1186/ar430410.1186/ar4304 ↗
9. 10.1038/nm.205010.1038/nm.2050 ↗
10. 10.1002/anie.20150228710.1002/anie.201502287 ↗
11. 10.1038/nm.372810.1038/nm.3728 ↗
12. 10.1002/anie.20140493010.1002/anie.201404930 ↗
13. 10.1002/art.2754210.1002/art.27542 ↗
14. 10.1136/annrheumdis-2010-14828810.1136/annrheumdis-2010-148288 ↗
15. 10.1038/nprot.2006.39310.1038/nprot.2006.393 ↗
16. 10.1039/C6CC03845J10.1039/C6CC03845J ↗
17. 10.1515/nanoph-2018-013410.1515/nanoph-2018-0134 ↗
18. 10.1080/05704928.2017.132331110.1080/05704928.2017.1323311 ↗
19. 10.1002/acr.2164910.1002/acr.21649 ↗
20. 10.1002/art.2734610.1002/art.27346 ↗
21. 10.1186/ar440110.1186/ar4401 ↗
22. 10.1359/JBMR.04020510.1359/JBMR.040205 ↗
23. 10.1097/BOR.0b013e3283369cb810.1097/BOR.0b013e3283369cb8 ↗
24. 10.1007/s10456-015-9477-210.1007/s10456-015-9477-2 ↗
25. 10.1186/ar57510.1186/ar575 ↗
26. 10.1097/BOR.0b013e32835a0fe110.1097/BOR.0b013e32835a0fe1 ↗
27. 10.1148/radiol.1211224610.1148/radiol.12112246 ↗
28. 10.1016/j.ydbio.2014.06.02010.1016/j.ydbio.2014.06.020 ↗
29. 10.1073/pnas.87.18.726010.1073/pnas.87.18.7260 ↗
30. 10.1038/nbt.169610.1038/nbt.1696 ↗
31. 10.2310/7290.2010.0003410.2310/7290.2010.00034 ↗
32. 10.1002/adfm.20170099510.1002/adfm.201700995 ↗
33. 10.1038/nmat447610.1038/nmat4476 ↗
34. 10.7150/thno.1122210.7150/thno.11222 ↗
35. 10.1007/s11307-015-0870-410.1007/s11307-015-0870-4 ↗
36. 10.1038/nbt.246810.1038/nbt.2468 ↗